Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib vs. Niraparib plus Bevacizumab in ctDNA-positive Advanced Ovarian Cancer After IDS
jRCT2031220732Active, not recruiting
- Sponsor
- Takeda
- Start
- Dec 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Randomised trial of niraparib and bevacizumab in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by Takeda. Primary endpoint: Progression-free survival. Started Dec 2023; status: active, not recruiting.
02
Drugs
niraparibbevacizumab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on jRCT2031220732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220732.